<DOC>
	<DOCNO>NCT03087539</DOCNO>
	<brief_summary>Exploratory Phase II Clinical Trial Evaluate Efficacy Safety Clotinab® ( Abciximab ) Acute Myocardial Infarction Patients : Multicenter , Randomized , Double-Blind , Placebo-controlled Parallel Group Trial</brief_summary>
	<brief_title>Exploratory P2 Trial Evaluate Efficacy Safety Clotinab® ( Abciximab ) Acute MI Patients</brief_title>
	<detailed_description>This study exploratory phase 2 Clinical Trial evaluate efficacy safety Clotinab® ( Abciximab ) acute myocardial infarction patient design multicenter , randomize , double-blinded , placebo-controlled parallel group study . The objective phase 2 clinical trial evaluate correlation infarct size major adverse cardiac event ( MACE ) acute myocardial infarction patient , prearrange percutaneous coronary intervention ( PCI ) , measure possibility use infarct size primary efficacy test variable phase 3 final confirmation safety efficacy . Also determine exploratively average variance estimation infarct size study drug placebo confirm safety efficacy study drug , compare placebo use estimation calculate sample size phase III clinical trial .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Abciximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoglobulin Fab Fragments</mesh_term>
	<criteria>Inclusion criterion 1 . Patients acute myocardial infarction ST segment , 1 mm , least 2 consecutive segment . 2 . Patients plan Percutaneous Coronary Intervention ( PCI ) Exclusion criterion 1 . History myocardial infarction 2 . History hypersensitivity aspirin , heparin , protein drug 3 . Bleeding disorder 4 . Thrombocytopenia ( &lt; 100,000unit/㎕ ) 5 . Cardiogenic shock , chronic atrial fibrillation , cancer 6 . Patients follow criterion : Implanted pacemaker , defibrillator , intracranial metallic implant , pregnant , etc 7 . Had history surgical operation within 4 week 8 . Participated clinical trial within 2 month</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>